πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 3 of 18

  1. US 12134631

    Hydrophilic linkers for antibody drug conjugates

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12127536

    Humanized M-CSF mice

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12123001

    Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12115216

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12110502

    Models of tauopathy

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12103960

    VEGF traps and mini-traps and methods for treating ocular disorders and cancer

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12096754

    Non-human animals having a humanized lymphocyte-activation gene 3

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12091440

    IL2 and peptide-MHC complex fusion proteins and methods of use thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12091449

    Anti-PfRH5 antibodies and antigen-binding fragments thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12090201

    Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12090193

    Glucagon-like peptide 1 receptor agonists and uses thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12091460

    Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12089575

    Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12084516

    Anti-C5 antibody combinations and uses thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12082565

    Non-human animals models of retinoschisis

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12083141

    Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12082566

    Rodent animals expressing human CR1

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12077570

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12077593

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12077587

    Anti-CD8 antibodies and uses thereof

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12077782

    Viral clearance by low pH hold

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12070502

    Process for reducing subvisible particles in a pharmaceutical formulation

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12070506

    Steroids and antibody-conjugates thereof

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12070460

    Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12065506

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12068729

    Anti-factor XII/XIIa antibodies and uses thereof

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12066246

    Target residual moisture content for lyophilized drug product

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12060428

    Anti-IL36R antibodies

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12060419

    CD79A chimeric antigen receptors

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12054533

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12054532

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12054557

    Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12053534

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12049489

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12049670

    Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12042538

    Methods of reducing particle formation and compositions formed thereby

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12037411

    Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12037388

    Anti-IL-33 antibodies and uses thereof

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12037401

    Anti-TrkB monoclonal antibodies and methods of use

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12036256

    Adoptive cellular therapy

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12036280

    High concentration protein formulation

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12036288

    Methods of using humanized FCΞ³R mice to assay Fc regions

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12030935

    Anti-PDGF-B antibodies and pharmaceutical composition thereof

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12029788

    Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12024570

    Anti-CTLA-4 antibodies and uses thereof

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12024556

    Anti-Staphylococcus antibodies and uses thereof

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12018259

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.